Systemic Activation of Inflammasomes and Frailty in Older Candidates to Kidney Transplantation
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age70+
SponsorUniversity Hospital, Bordeaux
About this trial
Kidney transplantation (KT) benefit-risk ratio assessment is a challenge in a growing population of older patients with end-stage kidney disease. A pre-KT frailty phenotype has been found predictive of post-KT complications, but biological mechanisms of frailty are poorly known is these patients. Frailty is associated with chronic low-grade inflammation in the older general population, possibly through the inflammasome pathway. Our main objective is to assess if systemic activation of inflammasomes is associated with frailty in older candidates to KT.
Eligibility criteria
Qualifiers
Age ≥ 70
Patient candidate to kidney transplantation (during assessment for inscription on the waiting-list, or during waiting time after effective inscription), without absolute contraindication
Free, informed and written consent signed by the participant and the investigator (at the latest, on the day of inclusion and before any examination required by the research).
Person affiliated or beneficiary of a social security scheme
Disqualifiers
Inclusion in an industrial study refusing co-inclusion in our study
Person under guardianship, assisted decision-making or under temporary guardianship
Trial design
Treatments tested in this trial
- Blood sample
- Geriatric assessment standardized
Treatment groups
60 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov